WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising a liquid carrier, valdecoxib; and a cyclodextrin;

wherein the cyclodextrin is present in an amount of not less than 5%, w/v, of the composition, and

wherein at least a substantial portion of the valdecoxib is in solubilized form in the liquid carrier and wherein at a given temperature, the weight ratio of said valdecoxib in solubilized form to said cyclodextrin is in a proportion of at least about 2.5% greater than is achievable in a substantially similar composition but which comprises less than 5%, w/v, of said cyclodextrin at the given temperature.

2. The composition of Claim 1 wherein said cyclodexrin amount is not less than about 7.5%, w/v, of the composition.
3. The composition of Claim 1 wherein said cyclodexrin amount is not less than about 15%, w/v, of the composition.
4. The composition of Claim 1 wherein said proportion is greater than at least about 5.0 %.
5. The composition of Claim 1 wherein said proportion is greater than at least about 10.0%.
6. The composition of Claim 1 wherein the cyclodextrin is an α-cylcodextrin and/or a β-cyclodextrin.
7. The composition of Claim 1 wherein the cyclodextrin is an at least partially etherified β-cyclodextrin.
8. The composition of Claim 1 wherein the cyclodextrin is a sulfoalkyl ether cyclodextrin and/or a hydroxyalkyl-β-cyclodextrin.
9. The composition of Claim 1 wherein the cyclodextrin is a sulfobutyl ether cyclodextrin and/or hydroxypropyl-β-cyclodextrin.
10. The composition of Claim 1 wherein the valdecoxib is present at a concentration of not less than about 1 mg/ml of the composition.
11. The composition of Claim 1 wherein the valdecoxib is present at a concentration of not less than about 2 mg/ml of the composition.
12. The composition of Claim 1 wherein the valdecoxib is present at a concentration of about 4 mg/ml to about 10 mg/ml.
13. The composition of Claim 1 wherein the liquid carrier comprises water suitable for

injection.

14. The composition of Claim 1 wherein (a) the valdecoxib is present at a concentration of about 4 mg/ml to about 10 mg/m; (b) the cyclodextrin is a sulfobutyl ether cyclodextrin and/or hydroxypropyl-β-cyclodextrin; (c) said cyclodexrin amount is not less than about 7.5%, w/v, of the composition; and (d) . said proportion is greater than at least about 5.0 %.
15. The method comprising administration of the composition of Claim 1 to a subject in need thereof.
16. The method of Claim 15 wherein said need is treatment and/or prevention of or from a cyclooxygenase-2 mediated disorder or condition.
17. The method of Claim 15 wherein said administration is once or twice daily.